The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | NGS vs flow cytometry for MRD assessment in NPM1-mutated AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and results of a study investigating the best technique to assess measurable residual disease (MRD) in patients with NPM1-mutated acute myeloid leukemia (AML). Dr Ravandi explains that whilst many US centers use next-generation sequencing (NGS) for MRD analysis, it may not be the most sensitive method to measure NPM1 clearance. In fact, the study revealed that flow cytometry is a better assay for sensing MRD in NPM1-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
